Polypharmacy among patients with hypertension attending primary healthcare centres

Safaa M. Alsanosi, PhD*a, Ahmed H. Mousa, BSc*c, Hind A. Ahmadini, MSc*b, Rawabi S. Qadhi, MSc*b, Nadeem Ikram, PhD*b, Alaa H. Felemban, PhD*b, Hamsah S. Alqashqri, MD*a, Nahla H. Hariri, PhD*b, Yosra Z. Alhindi, PhD*b, Nahla Ayoub, PhD*b

Introduction: Saudi Arabia has several hypertensive patients who require close attention and specialised care for their medications. Polypharmacy is one of the reasons for the failure of patient compliance with antihypertensive medications. Therefore, this study aims to gain a better perspective on polypharmacy in hypertensive patients attending primary healthcare (PHC) centres in Makkah, Saudi Arabia.

Methods: This was an observational, cross-sectional, descriptive study of hypertensive patients followed up at 10 PHC centres in Makkah, Saudi Arabia, from 1 July 2019 to 30 June 2022. Frequencies and percentages were used to present categorical data, and Pearson’s χ² test was used to measure differences. A P value less than 0.05 was considered statistically significant.

Results: A total of 506 patients were included in this study. The mean age of the patients was 60 years, and more than half (69%) were females. Regarding antihypertensive medication use, 64% were on antihypertensive combination therapy, 76% on dual therapy, 21% on triple therapy, and 3% on quadruple therapy. Moreover, 21% of the hypertensive patients were exposed to polypharmacy. There was a significant relationship (P < 0.001) between the overall number of chronic medications used per day and the duration of hypertension.

Conclusion: More clinical research is needed to identify the impact of polypharmacy on the quality of healthcare in PHC centres in general and hypertensive patients specifically in different regions of Saudi Arabia.

Keywords: Polypharmacy, Medical prescribing, antihypertensive, Saudi Arabia

HIGHLIGHTS
- Although it is a well-recognised problem, limited studies have investigated polypharmacy in Saudi Arabia.
- Our study is the first to examine polypharmacy among hypertensive patients in the Makkah region.
- Our results showed that more than half of hypertensive patients were on combination therapy.
- Our results showed that the rate of polypharmacy was associated with the duration of hypertension in patients.
- Although various approaches to decrease polypharmacy have been suggested, no considerable evidence from appropriately powered randomised controlled trials exists about their practicality for use in primary healthcare.

Hypertension is often an asymptomatic condition; its treatment includes blood pressure control (to reduce the risk of death or disability from cardiovascular disease, especially stroke, coronary artery disease and cardiac failure) without inducing adverse effects or otherwise interfering with patient well-being[4,5]. It is important to enhance compliance by selecting a drug regimen that both reduces adverse effects and minimises the number of doses required daily[6].

There is no consensus on the definition of polypharmacy in the literature; however, a numerical definition of five or more medications per day is mainly referred to[7,8]. In general, it is recommended to treat each chronic condition according to disease-specific guidelines. Still, in clinical practice, physicians do not

Introduction
Hypertension is one of the most important cardiovascular diseases in the modern world. It is a risk factor for the development of atherosclerotic cardiovascular diseases (including myocardial infarction, stroke and claudication)[1]. Hypertension management has improved significantly due to increased awareness of associated health risks, improved pharmacological management offered by primary care practitioners and availability of effective treatment options[1,2]. A lack of patient compliance is the most common reason for the failure of antihypertensive medications[3].

Polypharmacy. There was a significant relationship (P < 0.001) between the overall number of chronic medications used per day and the duration of hypertension.

Pharmacology and Toxicology, bDepartment of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, cCollege of Medicine and Surgery, Batterjee Medical College, Jeddah, dKing Fahad Central Hospital, Jazan, Saudi Arabia and eInstitute of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Umm Al-Qura University College of Medicine, Makkah 24375, Saudi Arabia. Tel.: + 00966504504080. E-mail: smsanosi@uqu.edu.sa (S.M. Alsanosi).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Annals of Medicine & Surgery (2023) 85:2545–2549
Received 17 February 2023; Accepted 30 April 2023
Published online 10 May 2023
http://dx.doi.org/10.1097/MS9.0000000000000818

HIGHLIGHTS
- Although it is a well-recognised problem, limited studies have investigated polypharmacy in Saudi Arabia.
- Our study is the first to examine polypharmacy among hypertensive patients in the Makkah region.
- Our results showed that more than half of hypertensive patients were on combination therapy.
- Our results showed that the rate of polypharmacy was associated with the duration of hypertension in patients.
- Although various approaches to decrease polypharmacy have been suggested, no considerable evidence from appropriately powered randomised controlled trials exists about their practicality for use in primary healthcare.

Polypharmacy. There was a significant relationship (P < 0.001) between the overall number of chronic medications used per day and the duration of hypertension.

Pharmacology and Toxicology, bDepartment of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, cCollege of Medicine and Surgery, Batterjee Medical College, Jeddah, dKing Fahad Central Hospital, Jazan, Saudi Arabia and eInstitute of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Umm Al-Qura University College of Medicine, Makkah 24375, Saudi Arabia. Tel.: + 00966504504080. E-mail: smsanosi@uqu.edu.sa (S.M. Alsanosi).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Annals of Medicine & Surgery (2023) 85:2545–2549
Received 17 February 2023; Accepted 30 April 2023
Published online 10 May 2023
http://dx.doi.org/10.1097/MS9.0000000000000818

HIGHLIGHTS
- Although it is a well-recognised problem, limited studies have investigated polypharmacy in Saudi Arabia.
- Our study is the first to examine polypharmacy among hypertensive patients in the Makkah region.
- Our results showed that more than half of hypertensive patients were on combination therapy.
- Our results showed that the rate of polypharmacy was associated with the duration of hypertension in patients.
- Although various approaches to decrease polypharmacy have been suggested, no considerable evidence from appropriately powered randomised controlled trials exists about their practicality for use in primary healthcare.

Polypharmacy. There was a significant relationship (P < 0.001) between the overall number of chronic medications used per day and the duration of hypertension.

Pharmacology and Toxicology, bDepartment of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, cCollege of Medicine and Surgery, Batterjee Medical College, Jeddah, dKing Fahad Central Hospital, Jazan, Saudi Arabia and eInstitute of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Umm Al-Qura University College of Medicine, Makkah 24375, Saudi Arabia. Tel.: + 00966504504080. E-mail: smsanosi@uqu.edu.sa (S.M. Alsanosi).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Annals of Medicine & Surgery (2023) 85:2545–2549
Received 17 February 2023; Accepted 30 April 2023
Published online 10 May 2023
http://dx.doi.org/10.1097/MS9.0000000000000818

HIGHLIGHTS
- Although it is a well-recognised problem, limited studies have investigated polypharmacy in Saudi Arabia.
- Our study is the first to examine polypharmacy among hypertensive patients in the Makkah region.
- Our results showed that more than half of hypertensive patients were on combination therapy.
- Our results showed that the rate of polypharmacy was associated with the duration of hypertension in patients.
- Although various approaches to decrease polypharmacy have been suggested, no considerable evidence from appropriately powered randomised controlled trials exists about their practicality for use in primary healthcare.
adjust or discuss the applicability of recommendations for patients with chronic diseases (including hypertension and diabetes mellitus), and following all guidelines for each medication a patient is taking will certainly result in polypharmacy[9,10].

Healthcare professionals have become concerned about preventing or minimising the negative outcomes of polypharmacy, including adverse drug reactions, drug–drug interactions, nonadherence to medications and greater healthcare costs[11]. However, although various approaches to decreasing polypharmacy and inappropriate medication prescribing have been suggested, no considerable evidence from appropriately powered randomised controlled trials exists about their practicality for use in primary healthcare (PHC) centres or their impact on patient health[12,13].

Saudi Arabia has a large number of hypertensive patients who require close attention and specific care for their medications[14]. Although it is a well-recognised problem, few studies have investigated polypharmacy in Saudi Arabia. Therefore, this study aims to gain a better perspective on polypharmacy among hypertensive patients attending PHC centres in the Makkah region, Saudi Arabia.

Materials and methods

Ethical approval

This study was approved by the Local Committee for Research Ethics, General Directorate of Health Affairs for the Makkah region, Saudi Arabia (H-02-K076-1903-095), under the Declaration of Helsinki.

Study design

This was an observational, cross-sectional, descriptive study of patients followed up at hypertension clinics from 1 July 2019 to 30 June 2022 at 10 PHC centres in the Makkah region, Saudi Arabia. Most of the data collection was performed before the coronavirus disease 2019 (COVID-19) pandemic. However, because of COVID-19 restrictions, we worked on and off to collect and complete the data.

Inclusion and exclusion criteria

The inclusion criteria were male and nonpregnant female patients, aged 18 years and over, who had a diagnosis of hypertension for at least 12 months, signed an informed consent form, had three or more visits to the clinic and took any prescription medication. The exclusion criteria included pregnant patients, the inability to provide informed consent and persons who were not taking any medication or were newly diagnosed or visiting the clinic for the first time.

Sample size and data collection

The sample size was calculated using Slovin’s formula, with a population size of 417 participants from a recently published study in Riyadh, Saudi Arabia, by Almutairi et al.[15], with a confidence interval of 95% and a margin of error of 5%. The World Health Organization has adopted the following definition of polypharmacy: the use of five or more medications per day[16].

All prescription medications taken by the patient were included, and according to this study, polypharmacy is related to all chronic medications (including antihypertensives and medications for comorbidities). Medications used on a weekly, bi-weekly or monthly basis were not included if they were used for less than 3 months. After obtaining informed consent, patients’ demographic and other relevant information was recorded, including file number, age, gender, height, weight, duration of hypertension, blood pressure and pulse readings, and the number and classes of medications used. Data were collected by interview, chart review, a check of all medications being used by the patient and the tracking of their current computerised drug prescriptions. The collected data were transferred to Microsoft Excel.

Statistical analysis

Data were analysed using SPSS version 23.0 (SPSS Inc.), and we presented categorical variables as frequencies and percentages. We used Pearson’s χ² test to measure any differences. A P value less than 0.05 was considered statistically significant.

Results

Patients’ demographic and baseline characteristics

A total of 506 patients were included in this study. The mean age of the patients was 60 years. Over two-thirds of them (69%) were females, while 31.3% were male. The mean body mass index of the patients was 28.5 kg/cm². The mean systolic and diastolic blood pressure for our study sample was 142/78. The mean pulse rate was 82 beats per minute. The mean of antihypertensive medications used by the patients was two. While 36% of the patients were on antihypertensive monotherapy, 64% were on antihypertensive combination therapy, comprising 76% on dual therapy, 21% on triple therapy and 3% on quadruple therapy. A total of 46% of the patients had antidiabetic medications, 9% had lipid-lowering medications, 3% had anticoagulation medications and 41% had medications for coexisting diseases, such as rheumatoid arthritis, gout and hypothyroidism (Table 1).

As shown in Table 2, the most commonly used class of antihypertensive medications is angiotensin-converting enzyme inhibitors (58%), followed by calcium channel blockers (54%), angiotensin II receptor blockers and diuretics (33%), beta-blockers (18%) and alpha-blockers (0.6%). Amlodipine (calcium channel blocker) was the most commonly used medication (91%), followed by valsartan (angiotensin II receptor blocker, 72%) and lisinopril (angiotensin-converting enzyme inhibitor, 41%).

In terms of the overall number of chronic medications (including antihypertensives and medications for comorbidities) used by the hypertensive patients, 79% used fewer than five medications per day, 12% used five medications per day and only 9% used more than five medications, as shown in Figure 1.

As shown in Table 3, Pearson’s χ² test was used to determine whether there was a dependent relationship between the overall number of chronic medications used per day and the duration of hypertension. The results indicated a significant relationship (P < 0.001).

Discussion

The present study aims to gain a better perspective on polypharmacy among hypertensive patients attending PHC centres in the Makkah region, Saudi Arabia, by collecting data from patients attending 10 PHC centres in Makkah, Saudi Arabia. Our study showed that the mean of antihypertensive medications used by the
patients was two, and 21% of the patients were exposed to five or more medications per day. Additionally, our findings demonstrated a significant association between the duration of hypertension and the overall number of chronic medications used per day.

The percentage of patients exposed to polypharmacy (considering the numerical definition of five or more medications per day) in the present study is lower than the percentages in other studies. For instance, a study conducted in Riyadh, Saudi Arabia, with 3009 patients showed that 50% of them were exposed to polypharmacy[16]. Another study done in Kuwait indicated that around 60% of participants were exposed to polypharmacy[17]. Furthermore, clinical studies conducted in the U.S. and Brazil showed that 39% and 32% of patients were exposed to polypharmacy, respectively[18,19]. Possible explanations for our results are the differences in definitions and approaches in clinical studies targeting polypharmacy, which make it difficult to describe polypharmacy and measure the safety and appropriateness of therapy in the clinical setting[7,20]. For instance, some definitions include a range from the use of two or more medications for more than 240 days to five to nine medications for 90 days or more[21,22].

### Table 1
Demographic and baseline characteristics of the sample population.

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29</td>
</tr>
<tr>
<td>Duration of being diagnosed with hypertension (years)</td>
<td>8</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>142</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>78</td>
</tr>
<tr>
<td>Pulse rate (BPM)</td>
<td>82</td>
</tr>
<tr>
<td>Number of medications used for hypertension</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>373 (69)</td>
</tr>
<tr>
<td>Males</td>
<td>133 (31)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antihypertensive medications use</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients on antihypertensive monotherapy</td>
<td>182 (36)</td>
</tr>
<tr>
<td>Patients on antihypertensive combination therapy</td>
<td>324 (64)</td>
</tr>
<tr>
<td>Patients on dual antihypertensive therapy</td>
<td>247 (76)</td>
</tr>
<tr>
<td>Patients on triple antihypertensive therapy</td>
<td>68 (21)</td>
</tr>
<tr>
<td>Patients on quadruple antihypertensive therapy</td>
<td>9 (3)</td>
</tr>
</tbody>
</table>

### Table 2
Classes of antihypertensive medications.

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin-converting enzyme inhibitors</td>
<td>202 (58)</td>
</tr>
<tr>
<td>Captopril: 25 mg, 50 mg, 100 mg</td>
<td>93 (32)</td>
</tr>
<tr>
<td>Enalapril: 5 mg, 10 mg</td>
<td>7 (2)</td>
</tr>
<tr>
<td>Perindopril: 5 mg, 10 mg</td>
<td>68 (23)</td>
</tr>
<tr>
<td>Lisinopril: 5 mg, 10 mg</td>
<td>121 (41)</td>
</tr>
<tr>
<td>Ramipril: 5 mg</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Quinapril: 5 mg</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Angiotensin II receptor blockers</td>
<td>168 (33)</td>
</tr>
<tr>
<td>Losartan: 50 mg</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Olmesartan: 20 mg, 40 mg</td>
<td>11 (7)</td>
</tr>
<tr>
<td>Irbesartan: 150 mg, 300 mg</td>
<td>9 (5)</td>
</tr>
<tr>
<td>Valsartan: 80 mg, 160 mg</td>
<td>121 (72)</td>
</tr>
<tr>
<td>Candesartan: 16 mg</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Telmisartan: 40 mg, 80 mg</td>
<td>18 (11)</td>
</tr>
<tr>
<td>Azilsartan: 80 mg</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>276 (54)</td>
</tr>
<tr>
<td>Amlodipine: 5 mg, 10 mg</td>
<td>252 (91)</td>
</tr>
<tr>
<td>Nifedipine: 30 mg, 60 mg</td>
<td>24 (9)</td>
</tr>
<tr>
<td>Diuretics</td>
<td>168 (33)</td>
</tr>
<tr>
<td>Furosemide: 40 mg</td>
<td>23 (14)</td>
</tr>
<tr>
<td>Hydrochlorothiazide: 12.5 mg, 25 mg</td>
<td>35 (21)</td>
</tr>
<tr>
<td>Indapamide: 1.5 mg</td>
<td>85 (51)</td>
</tr>
<tr>
<td>Chlorothiazide: 25 mg</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Amlodipine: 25 mg</td>
<td>6 (4)</td>
</tr>
<tr>
<td>Bumetanide: 1.5 mg</td>
<td>3 (2)</td>
</tr>
<tr>
<td>Metolazone: 2.5 mg, 5 mg</td>
<td>14 (8)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>90 (18)</td>
</tr>
<tr>
<td>Atenolol: 50 mg, 100 mg</td>
<td>34 (38)</td>
</tr>
<tr>
<td>Bisoprolol: 2.5 mg, 5 mg</td>
<td>46 (51)</td>
</tr>
<tr>
<td>Metoprolol: 5 mg</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Carvedilol: 5 mg, 25 mg</td>
<td>5 (6)</td>
</tr>
<tr>
<td>Amodiol: 25 mg</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Labetalol: 100 mg</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Beta-blockers: Doxazosin</td>
<td>3 (1)</td>
</tr>
</tbody>
</table>

ALT, Alanine transaminase; AST, Aspartate transaminase; BPM, beats per minute; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Figure 1. Overall number of chronic medications used per day.
Conclusions

In our study, almost two-thirds of hypertensive patients were on dual therapy of antihypertensive medication. Considering the numerical definition of five or more medications per day, 21% of hypertensive patients were exposed to polypharmacy. Furthermore, there was a significant relationship between the total number of chronic medications used per day and the duration of hypertension. The impact of polypharmacy on medication adherence and the control of underlying diseases in Saudi Arabia is unknown and needs to be studied at various levels of healthcare institutions in different regions of Saudi Arabia. Healthcare providers can help manage polypharmacy by offering recommendations simplifying medication regimens and lowering medication numbers to optimise healthcare quality and improve drug safety among hypertensive patients.

Ethical approval

This study was approved by the Local Committee for Research Ethics, General Directorate of Health Affairs for the Makkah region, Saudi Arabia (H-02-K076-1903-095), under the Declaration of Helsinki.

Consent

Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Sources of funding

This research received no external funding.

Author contribution


Conflicts of interest disclosure

The authors declare no conflicts of interest.

Research registration unique identifying number (UIN)

1. Name of the registry: not applicable.
2. Unique identifying number or registration ID: not applicable.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): not applicable.

Guarantor
Safaa M. Alsanosi.

Provenance and peer review
The paper was not invited.

Data availability statement
None.

References

[34] Diaconu CC, Cozma MA, Dobrică EC, et al. Polypharmacy in the management of arterial hypertension-friend or foe? Medicina (Kaunas) 2021;57:1288.